{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:35:18Z","timestamp":1771522518500,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jphs.2025.12.006","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:14:40Z","timestamp":1766621680000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitor-induced glycosuria improves steatotic liver disease in parallel with enhanced ureagenesis in ob\/ob mice"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-8952","authenticated-orcid":false,"given":"Satoshi","family":"Kidoguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ohsaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Titze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2025.12.006_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jphs.2025.12.006_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jphs.2025.12.006_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221122478","article-title":"Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK biobank","volume":"13","author":"Ma","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jphs.2025.12.006_bib4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jphs.2025.12.006_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib14","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-Week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2025.12.006_bib15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2025.12.006_bib16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1440-1746.2006.04698.x","article-title":"Significant correlations between severe fatty liver and risk factors for metabolic syndrome","volume":"22","author":"Hsiao","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jphs.2025.12.006_bib17","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/nu14173531","article-title":"Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db\/db mice","volume":"14","author":"Hata","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jphs.2025.12.006_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261310","article-title":"Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model","volume":"17","author":"Morishita","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2025.12.006_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbrc.2021.04.012","article-title":"Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: role of prostaglandin E","volume":"557","author":"Yoshino","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jphs.2025.12.006_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4254\/wjh.v12.i7.350","article-title":"Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling","volume":"12","author":"Suga","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jphs.2025.12.006_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/03007995.2025.2463952","article-title":"The systemic immune inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease","volume":"41","author":"Kosekli","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jphs.2025.12.006_bib23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"Fahed","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40360-025-00898-z","article-title":"Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis","volume":"26","author":"Fan","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jphs.2025.12.006_bib25","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1172\/JCI88532","article-title":"High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation","volume":"127","author":"Kitada","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jphs.2025.12.006_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13629","article-title":"Adaptive physiological water conservation explains hypertension and muscle catabolism in experimental chronic renal failure","author":"Kovarik","year":"2021","journal-title":"Acta Physiol"},{"key":"10.1016\/j.jphs.2025.12.006_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13628","article-title":"Aestivation motifs explain hypertension and muscle mass loss in mice with psoriatic skin barrier defect","author":"Wild","year":"2021","journal-title":"Acta Physiol"},{"key":"10.1016\/j.jphs.2025.12.006_bib28","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1038\/s41440-024-01874-6","article-title":"Blood pressure alteration associated with abnormal body electrolyte and water balance in colitis mice","volume":"47","author":"Kundo","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jphs.2025.12.006_bib29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s10038-019-0614-4","article-title":"Urea cycle disorders-update","volume":"64","author":"Matsumoto","year":"2019","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jphs.2025.12.006_bib30","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jphs.2025.12.006_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","article-title":"Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation","volume":"17","author":"Marton","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jphs.2025.12.006_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/DMSO.S232279","article-title":"DHA protects against hepatic steatosis by activating Sirt1 in a high fat diet-induced nonalcoholic fatty liver disease mouse model","volume":"13","author":"Luo","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jphs.2025.12.006_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/HJH.0000000000000871","article-title":"Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome","volume":"34","author":"Rahman","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.jphs.2025.12.006_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nutres.2020.02.001","article-title":"Siphonaxanthin, a carotenoid from green algae Codium cylindricum, protects Ob\/Ob mice fed on a high-fat diet against lipotoxicity by ameliorating somatic stresses and restoring anti-oxidative capacity","volume":"77","author":"Zheng","year":"2020","journal-title":"Nutr Res"},{"key":"10.1016\/j.jphs.2025.12.006_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001303","article-title":"Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic","volume":"8","author":"Kusakabe","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jphs.2025.12.006_bib36","article-title":"Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats","author":"Kidoguchi","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jphs.2022.04.008","article-title":"Tolvaptan induces body fluid loss and subsequent water conservation in normal rats","volume":"149","author":"Kidoguchi","year":"2022","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jphs.2025.12.006_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in Obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2025.12.006_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2025.12.006_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jphs.2025.12.006_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/JME-22-0022","article-title":"MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH","volume":"69","author":"Wang","year":"2022","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.jphs.2025.12.006_bib43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jphs.2025.12.006_bib44","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jphs.2025.12.006_bib45","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jphs.2025.12.006_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjms.2016.08.015","article-title":"Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats","volume":"352","author":"Chen","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib47","first-page":"82","article-title":"Regulation of renal urea transport by vasopressin","volume":"122","author":"Sands","year":"2011","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.jphs.2025.12.006_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/cs0690231","article-title":"The effect of arginine vasopressin on ureagenesis in isolated rat hepatocytes","volume":"69","author":"Drew","year":"1985","journal-title":"Clin Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1172\/JCI37672","article-title":"Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure","volume":"120","author":"D'Apolito","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jphs.2025.12.006_bib50","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3906\/sag-1502-144","article-title":"The relationship between blood urea nitrogen levels and metabolic, biochemical, and histopathologic findings of nondiabetic, nonhypertensive patients with nonalcoholic fatty liver disease","volume":"46","author":"Er\u00e7in","year":"2016","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jphs.2025.12.006_bib51","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2025.12.006_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175194","article-title":"Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure","volume":"931","author":"Shiraki","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2025.12.006_bib53","doi-asserted-by":"crossref","first-page":"898","DOI":"10.4093\/dmj.2018.0257","article-title":"A lower baseline urinary glucose excretion predicts a better response to the sodium glucose cotransporter 2 inhibitor","volume":"43","author":"Hwang","year":"2019","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jphs.2025.12.006_bib54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.34067\/KID.0000000621","article-title":"Familial renal glucosuria and potential pharmacogenetic impact on sodium-glucose Cotransporter-2 inhibitors","volume":"6","author":"Allaire","year":"2025","journal-title":"Kidney360"},{"key":"10.1016\/j.jphs.2025.12.006_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12902-024-01690-6","article-title":"Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study","volume":"24","author":"Isogawa","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jphs.2025.12.006_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.475","article-title":"Effects of empagliflozin-induced glycosuria on weight gain, food intake and metabolic indicators in mice fed a high-fat diet","volume":"7","author":"Nguyen","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jphs.2025.12.006_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157672","article-title":"Sodium-glucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice","volume":"11","author":"Atageldiyeva","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2025.12.006_bib58","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1042\/CS20190863","article-title":"Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats","volume":"133","author":"Swe","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jphs.2025.12.006_bib59","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00592-025-02488-1","article-title":"Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes","volume":"62","author":"Sun","year":"2025","journal-title":"Acta Diabetol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:53:49Z","timestamp":1771520029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861325001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1347861325001173"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2025.12.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor-induced glycosuria improves steatotic liver disease in parallel with enhanced ureagenesis in ob\/ob mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}